Allergy Therapeutics Share Price (AGY)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Allergy Therapeutics	LSE:AGY	London	Ordinary Share	GB00B02LCQ05	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.25p	-0.94%	26.25p	215,656	09:23:12
Bid Price		Offer Price	High Price	Low Price	Open Price
25.50p		27.00p	26.50p	26.25p	26.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	64.1	-2.0	-0.4	-	158.58

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Geiger Count. S (GCS), Port Erin (PEBI)

Allergy Therapeutics (AGY) Latest News

Allergy Therapeutics News

Date	Time	Source	Headline
29/5/2018	11:19	ALNC	Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests
29/5/2018	07:53	ALNCF	Alliance News Flash Headline
29/5/2018	07:01	RNSNON	Allergy Therapeutics PLC Positive data with house-dust mite immunotherapy
21/5/2018	11:49	ALNC	Allergy Therapeutics Reports Positive Results From Grass Pollen Study
21/5/2018	07:00	UKREG	Allergy Therapeutics PLC Positive top-line results from Grass Ph II study
14/5/2018	12:24	ALNC	Allergy Therapeutics Gets Positive Indications In Latest MCT Study
14/5/2018	07:00	RNSNON	Allergy Therapeutics PLC Publication of MCT Adjuvant Data
16/3/2018	17:30	ALNC	DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake
16/3/2018	15:38	UKREG	Allergy Therapeutics PLC Grant of Awards under Long Term Incentive Plan
16/3/2018	12:53	UKREG	Allergy Therapeutics PLC Director/PDMR Shareholding

More Allergy Therapeutics News

Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Share Charts

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Intraday Allergy Therapeutics Chart

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date	Time	Title	Posts
07/6/2018	17:34	Allergy Therapeutics - AGY -	3,434
14/7/2016	21:04	Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)	1
16/12/2015	10:24	Allergy Therapeutics-Transforming Allergy Treatment	26
03/2/2012	13:58	Ready to ROCKET?	-
04/12/2005	12:00	AGY - Allergy Therapeutics	79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
15:26:31	25.90	3,861	1,000.00	O
15:03:28	25.90	28,000	7,252.00	O
14:49:13	25.90	1,250	323.75	O
12:46:45	25.58	400	102.30	O
11:19:25	25.58	909	232.48	O

View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Date	Subject
18/6/2018 09:20	Allergy Therapeutics Daily Update: Allergy Therapeutics is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 26.50p. Allergy Therapeutics has a 4 week average price of 25p and a 12 week average price of 23p. The 1 year high share price is 39.50p while the 1 year low share price is currently 23p. There are currently 604,117,768 shares in issue and the average daily traded volume is 279,320 shares. The market capitalisation of Allergy Therapeutics is £158,580,914.10. Read Full Thread Reply
22/5/2018 18:51	gersemi: Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018 Read Full Thread Follow Reply
22/11/2017 09:49	jpuff: Why the collapse in the share price? Read Full Thread Follow Reply
21/9/2017 18:32	gersemi: Tipped in the IC Tip Update: Buy at 32.3p Tip style - GROWTH Risk rating -HIGH Timescale - LONG TERM Our previous tip -We said BUY at 19.8p on 21 Jul 2016 Tip performance to date - +63% By Megan Boxall The US allergy pharmaceuticals market has the potential to be very lucrative. Roughly 18m Americans sniff and itch their way through the hay fever season each year and, at present, treatment options are limited. But it is also a notoriously tricky sector to navigate. Allergy Therapeutics (AGY) is proof of that, gaining the go-ahead for the phase II clinical trial of its new grass allergy medicine – Pollinex Quattro (PQ) – after 10 years. In 2007, Allergy’s final trial into the efficacy of PQ was put on hold after a participant reported numbness and weakening, which regulators couldn’t be sure had nothing to do with the treatment. That hold was only lifted in 2011, and since then the group has failed to show US regulators an acceptable dosage of the drug. But with demand for PQ so strong, Allergy has been given the go-ahead to try again. The newest dosing study will begin imminently, according to management, and is expected to release results by the second half of 2018. If approved, PQ will be the first injectable allergy treatment available in the US. But as well as sidestepping tight regulation, Allergy Therapeutics must hurdle another demon of the allergy drugs market: the placebo effect. In 1999 a food allergy vaccine made by Peptide Therapeutics successfully helped 75 per cent of patients on a clinical trial tolerate more of the food they were allergic to. Unfortunately, a similar number of patients on the placebo treatment responded the same way, meaning the trial was deemed a failure. It was a similar story at Circassia (CIR) last year when its cat allergy treatment failed to show any significant benefits above the placebo drug, which had improved symptoms by 59 per cent. Many academic studies have found this high placebo effect to be common in allergy drugs trials, but no-one can fully explain why. Allergy Therapeutics should be more immune to placebo effect than its peers. PQ has already successfully improved the symptoms of more than 250,000 patients and is marketed in seven countries. Moreover, the trial has not been designed using the self-report measures that have caused problems for many allergy studies; instead patients’ eyes will be observed for signs of improvement before and after treatment. IC View Investors have been slow to forgive Allergy Therapeutics for its US misfortunes. The share price has gained good momentum in the past few months, but at 32p it is still far from its 2006 highs. There are factors to be wary of that are outside of the company’s control, such as tight US allergy regulation, but demand for PQ is clearly high. If Allergy can crack the tough US regulatory environment, the financial rewards could be big. Buy. Last IC View: Buy, 25p, 03 Apr 2017 - Read Full Thread Follow Reply
29/3/2017 07:53	jimmyloser: Rich, Perhaps they are keeping their powder dry for another RNS! The name of the game here now is to get that share price up before they raise more cash. impo/dyor. Read Full Thread Follow Reply
01/2/2017 19:52	jimmyloser: Upside still to be seen according to analyst. Allergy Therapeutics (LON:AGY) will take its Polyvac vaccine for peanut allergy into a phase I clinical trial after it delivered positive pre-clinical results. The findings showed a single dose of the company's unique adjuvant when combined with recombinant peanut allergen successfully protected against the serious allergic reaction anaphylaxis. The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments. “Hundreds of patients die each year in the United States as a result of food allergies (mainly peanut) and we are committed to saving these lives,” said Allergy Therapeutics chief executive Manuel Llobet. “This peanut vaccine programme complements our current range of marketed ultra-short course vaccines in terms of safety, efficacy and improved patient convenience." The shares rose 6% in afternoon trade to 27.5p. However the company’s broker, finnCap, thinks they have further to go. Analyst Mark Brewer points out Allergy trades on an enterprise value/sales multiple of just two-times when its peers are on 3.2-times. He reckons the shares are worth 43p each with “substantial further upside” as its hay fever drug Pollinex Quattro progresses through the development phases. “We currently attribute no value to Polyvac Peanut and will re-assess as it moves into human studies,” said Brewer. ---adds broker comment, share price--- Read Full Thread Follow Reply
06/1/2017 16:18	audigger: An encouraging start to the New Year..... Allergy Therapeutics plc 92.8% Potential Upside Indicated by finnCap Allergy Therapeutics plc with EPIC/TICKER LON:AGY had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at finnCap. Allergy Therapeutics plc are listed in the Health Care sector within AIM. finnCap have set their target price at 40 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 92.8% from the opening price of 20.75 GBX. Over the last 30 and 90 trading days the company share price has increased 0.67 points and increased 0.57 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 21.27 GBX and the 200 Day Moving Average price is recorded at GBX. The 1 year high share price is 30 GBX while the year low stock price is currently 17.25 GBX. There are currently 598,491,373 shares in issue with the average daily volume traded being 86,871. Market capitalisation for LON:AGY is £122,989,973 GBP. Read Full Thread Follow Reply
15/10/2016 11:38	lordshaw: iii article: In a week when the FTSE 100 finally made an all-time high there were surprisingly few big winners among either the large or mid-caps. A three-day losing streak for the blue-chip index clearly took some froth out of the market, which is why we cast our net a bit wider in search of our Share of the week. In fact, we headed all the way to AIM where an old favourite was causing a stir. We last covered Allergy Therapeutics (AGY) in September following full-year results. Revenue had risen fast, but heavy R&D spend meant big full-year losses and a possible delay to profitability. However, one analyst reckoned an enterprise value (EV)/sales ratio of just 1.6 times made the shares "very cheap", with peers trading on a ratio of three times. It's why Paul Cuddon at Numis slapped a 37p price target on the shares. That article - Allergy Therapeutics tipped to bounce back - was nearly three weeks ago, and things have really taken off since. In the days following our write-up, directors opened their wallets, snapping up 280,000 Allergy shares at 17.75-19.25p. Chief executive Manuel Llobet kicked things off, buying 100,000 at 18p. Finance director Nicolas Wykeman picked up 150,000 at 17.75p, before chairman Peter Jensen bagged 30,000 at 19.25p. This Friday, the share price peaked at 25p, up 45% since the results. It's also a five-month high, and just a penny from the 50% Fibonacci retracement of the decline from the October 2015 best at 35p. Clearly, the market also liked news Monday that Allergy would present data at the World Vaccine Congress, demonstrating how its adjuvants can make "significant improvements" in the effectiveness of malaria vaccines. Data also implies "highly significant" potential for this novel adjuvant system in infectious disease applications using Allergy's Bencard Adjuvant Systems (BAS) technology, we're told. Panmure Gordon has been a fan for ages, and remains a buyer, believing Allergy could be worth 53p a share in time. The broker's sum-of-the-parts valuation is based on enterprise value/sales analysis of specialty pharma and allergy peers for calendar year 2017, estimated balance sheet cash and net present value of its Pollinex Quattro hay fever treatment. Read Full Thread Follow Reply
29/9/2016 18:14	jimmyloser: From elsewhere on the web Allergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon by: Amilia Stone 26th September 2016 Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP. Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World. Read Full Thread Follow Reply
05/3/2014 07:48	jimmyloser: I have thought of that and have read the prospectus and cannot see why they would at this stage. Having read that prospectus, I really am baffled as to why AGY share price is in pennies NO RAMP INTENDED. There have been encouraging signs that the board are now starting to market the company better. I repeat myself again. THIS MONTH IS HUGE FOR ALL INVOLVED HERE We have results on the 24th and 'hopefully' some solid USA news along with the Circassia floatation. I am shamefaced but will openly admit that when I bought into Allergy in January that I didn't realise that I had a potentially massive tiger by the tail. Really is the best money I have invested. Read Full Thread Follow Reply
20/2/2014 13:59	audigger: Looks like the demand for these is still high and the availability limited hence another leg-up. Long may it continue. Clealry there is a linear relationship between the AGY share price and the miles that Cube's dog gets walked........ Read Full Thread Follow Reply

Allergy Therapeutics share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:42 V: D:20180618 17:30:28